Glioblastoma (GBM) is an incurable and aggressive primary brain tumor in adults that even with surgical resection, radiotherapy and chemotherapy, median survival is 14.6 months. Indoleamine 2,3 dioxygenase 1 (IDO1) is a tryptophan catabolic enzyme expressed in GBM that suppresses tumor immunity and contributes to the pathogenesis of the disease. This proposal seeks to determine the impact of IDO1 inhibition, alone, and in combination with standard of care agents, and/or experimental immune-based strategies that are either already in, or ready for immediate translation into clinical trials. The following treatment paradigms will be focused on adult malignant glioma in the CNS.
|Effective start/end date||7/19/16 → 7/18/17|
- Pfizer Inc. (Agmt 07/19/16)